News

CF treatment Kaftrio improves lung function: Danish study

Cystic fibrosis (CF) patients saw improved lung function after one year of treatment with Kaftrio, sold as Trikafta in the U.S., a study found. The benefits were seen regardless of age, disease severity, or prior CFTR modulator treatment. “Using high-resolution data from a nationwide real-world setting, our study…

Risk of cardiovascular disease may rise for adults using Kaftrio/Trikafta

In adults with cystic fibrosis (CF), six of months treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) led to lower levels of biomarkers of inflammation, but higher blood levels of fat-like molecules considered to be cardiovascular risk factors, according to a recent study in Italy. While highly effective, the triple-combination therapy — available…

Investment to support CMTX-101 testing for chronic lung infections

Clarametyx Biosciences has announced an investment from Kineticos AMR Accelerator (KAMRA) Fund to support the development of CMTX-101, a non-antibiotic treatment candidate for persistent bacterial lung infections in people with cystic fibrosis (CF). This investment, which extends the company’s $33-million financing completed last year, will contribute…

Use of routine therapies in CF lower with Kaftrio (Trikafta): Study

People with cystic fibrosis (CF) saw sustained reductions in the use of several other CF therapies after two years of treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor), with airway medications and antibiotics being the most reduced, according to a real-world study from Denmark. “This study adds evidence of the real-world impact…

Registration now open for CF Foundation’s BreatheCon 2025

Registration is now open for BreatheCon 2025, an annual online event hosted by the Cystic Fibrosis Foundation that aims to foster connections between adults with cystic fibrosis (CF). This year’s BreatheCon will take place Feb. 7-8. Registration and additional information about the virtual event is available on the…